- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07826975
Assessment of Changes in Autonomy Through Analysis of Smartphone Usage Data in Patients With Alzheimer's Disease (AUMASMART)
Alzheimer's disease is the leading cause of dementia worldwide. The first cognitive function to be affected is memory. As the disease progresses, other cognitive systems are affected, leading to a gradual loss of independence for the patient. This loss of independence is at the heart of the psychosocial and medico-economic challenges posed by Alzheimer's disease. Functional independence refers to the patient's ability to perform activities of daily living. The evolution of autonomy varies significantly from one individual to another, and a specific, personalized assessment is necessary in order to offer appropriate care and services. There is a link between patient autonomy and psycho-behavioral disorders. Early identification of loss of autonomy in connection with psycho-behavioral disorders would allow specific treatment to be put in place.
The study hypothesis is that there is a link between changes in smartphone data and changes in the independence of patients with AD.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Adrien JULIAN, MD
- Telefoonnummer: +33 05.49.44.44.44
- E-mail: adrien.julian@chu-poitiers.fr
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- Age ≥ 60 years
- Patient consulting on routine care at a memory resource and research center for Alzheimer's disease defined by cognitive memory complaints from the patient or their family and friends, evidence of impaired verbal episodic memory storage in FCSRT defined by a sum of FR values less than 17/48 and a sum of CR values less than 40/48 compared to the patient's age and socio-cultural level and no criteria on other neuropsychological tests, progressive decline over at least 6 months affecting independence, and if a brain MRI, a lumbar puncture, and/or an 18FDG PET scan were performed as part of the patient's routine care, the results must be consistent with a diagnosis of MA.
- Patient with a smartphone for their exclusive use that is compatible with the installation of the IMASMART application on Android
- No sensory impairment (vision or hearing impairment) that could compromise the use of a smartphone
- Absence of major anxiety-depressive disorder defined by a HAD score > 16
- Patient an caregiver not objecting to participating in the study
Exclusion Criteria:
- Inability to perform the Mini-Mental State Examination or score < 17
- Other neurodegenerative disorders
- Severe, unstable psychiatric disorders
- Terminal phase of a severe illness
- Other conditions that may compromise the use of a smartphone
- Patients with an iPhone
- MRI evidence of a lesion that may contribute to cognitive impairment (stroke, tumors, etc.)
- Refusal to install the application
- People residing in a residential care for senior or any other medical facility
- Individuals benefiting from enhanced protection, namely individuals deprived of their liberty by judicial or administrative decision, adults under legal protection, and finally, patients in emergency situations.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Alzheimerpatiënten
|
Collection of Android smartphone usage
MMSE, FCSRT, FAB, TMT, verbal fluency test, Rey figure, BBEP, langage assesments and HAD scale
IADL Amsterdam assessed by the caregiver
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Comparison of changes in smartphone usage data and battery life collected at 0 and 18 months
Tijdsspanne: From enrollment to the end of participation at 18 months
|
To measure the relationship between variations in smartphone usage data-represented as a single parameter created through a mathematical combination-and variations in the Amsterdam IADL questionnaire between 0 and 18 months.
|
From enrollment to the end of participation at 18 months
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie stoel: Céline ABONNEAU, Poitiers University Hospital
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Hersenziekten
- Ziekten van het centrale zenuwstelsel
- Ziekten van het zenuwstelsel
- Psychische aandoening
- Neurocognitieve stoornissen
- Dementie
- Tauopathieën
- Neurodegeneratieve ziekten
- Ziekte van Alzheimer
- Kwaliteit, toegang en evaluatie van de gezondheidszorg
- Onderzoekstechnieken
- Epidemiologische methoden
- Evaluatiemechanismen voor gezondheidszorg
- Kwaliteit van de gezondheidszorg
- Volksgezondheid
- Milieu en volksgezondheid
- Gegevensverzameling
Andere studie-ID-nummers
- 2025-A01157-42
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .